TRADE NEWS: Agilent Technologies Inc. and Integrated Diagnostics Enter Strategic Partnership to Develop Protein-Based Assays for Early Disease Detection

Published: Jan 10, 2012

SANTA CLARA, Calif. & SEATTLE--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) and Integrated Diagnostics today announced a strategic partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes.

Integrated Diagnostics, an emerging leader in molecular diagnostics, is creating large-scale, blood-based molecular diagnostics that leverage advances in proteomics and genomics to detect diseases such as lung cancer and Alzheimer’s at their earliest stages. Agilent manufactures a wide range of analytical instrumentation, including liquid chromatography, mass spectrometry and automation systems. Officials of both organizations see an opportunity to rapidly turn medical breakthroughs into diagnostic assays by combining efforts to focus on protein and peptide biomarkers of disease.

Back to news